Hereditary partial deficiency of plasminogen activator inhibitor-1 associated with a lifelong bleeding tendency

International Journal of Hematology

Volumn 64, Issue 1, 1996, Pages 61-68

  Takahashi, Yukihiro ^a   Tanaka, Taeko ^a   Minowa, Hideki ^a   Ookubo, Yoshiaki ^a   Sugimoto, Mitsuhiko ^a   Nakajima, Mitsuru ^a   Miyauchi, Yoshizumi ^a   Yoshioka, Akira ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bleeding tendency; Hereditary I; Partial deficiency of PAI 1; Plasminogen activator inhibtor 1(PAI 1)

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANEXAMIC ACID;

ARTICLE; BLEEDING TENDENCY; CLINICAL ARTICLE; ENZYME DEFICIENCY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0030200498     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/0925-5710(96)00460-4     Document Type: Article

References (24)

1. [1] Lijnen HR, Collen D. Natural inhibitors of fibrinolysis. In: Bloom A, and Thomas DP. (eds). Haemostasis and Thrombosis, 2nd Edn. Edinburgh: Churchill Livingstone, 1987;255-266.
2. [2] Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemostas Thromb 1989;9:87-115.
3. [3] Ginsburg D, Zeheb R, Yang AY, Rafferty UM, Andreasen PA, Nielsen L, Dan K, Lebo RV, Gelehrter TD. cDNA cloning of human plasminogen activator-inhibitor from endotherial cells. J Clin Invest 1986;78:1673-1680.
4. [4] Erickson LA, Schleef RR, Ny T, Loskutoff DJ. The fibrinolytic system of the vascular wall. Clin Haematol 1985;14:513-530.
5. [5] Erickson LA, Hekman CM, Loskutoff DJ. The primary plasminogen activator inhibitors in endothelial cells, platelets, serum and plasma are immunologically related. Proc Natl Acad Sci USA 1985;82:8710-8714.
6. [6] Van Mourik JA, Lawrence DA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (anti-activator) synthesized by endothelium cells. J Biol Chem 1989;259:14914-14921.
7. [7] Erikson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in platelets. J Clin Invest 1984;74:1465-1472.
8. [8] Booth NA, Anderson JA, Bennet B. Platelet release protein which inhibits plasminogen activators. J Clin Pathol 1985;38:825-830.
9. [9] Sprengers ED, Akkerman JWN, Jansen BG. Blood platelet plasminogen activator inhibitor: two different pools of endothelial cell type plasminogen activator inhibitor in human blood. Thrombostas Haemostas 1986;55: 325-329.
10. [10] Schleef RR, Higgins DL, Pillemer E, Levitt LJ. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 1989;83:1747-1752.
11. [11] Dieval J, Nguyen G, Gress S, Delobel J, Kruithof EKO. A life long bleeding disorder associated with a deficiency of plasminogen activator type 1. Blood 1991;77:528-532.
12. [12] Lee MH, Vosburgh E, Anderson K, McDonagh J. Deficiency of plasma plasminogen activator inhibitor 1 results in hyperfibrinolytic bleeding. Blood 1993;81:2357-2362.
13. [13] Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D. Complete deficiency of plasminogen-activator type 1 due to a frame shift mutation. N Engl J Med 1992;327:1729-1733.
14. [14] Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D. A new variant of von Willebrand disease with defective binding to factor VIII. Blood 1989;74:1591-1599.
15. [15] Nishikubo T, Takahashi Y, Morii N, Fukui H. The binding of von Willebrand factor to collagen in normal in type 1 but defect in variants (type IIA, IIB and IIC) of von Willebrand disease. Thrombos Haemostas 1991;65:1128.
16. [16] Girma JP, Takahashi Y, Yoshioka A, Diaz J, Meyer D. Ristocetin and botrocetin involve two distinct domains of von Willebrand factor binding to platelet membrane glycoprotein Ib. Thrombostas Haemostas 1990;64: 326-332.
17. [17] Mikami S. Studies on platelet aggregation activity of bovine factor VIII; effects of different kinds of carbohydrate oxidases and other reagents. J Nara Med Assoc 1978;29:9-21.
18. [18] Takahashi Y, Tanaka T, Nakajima M, Yoshioka A, Fukui H, Miyauchi Y, Mii Y, Tamai S. Intramedullary multiple hematomas in siblings with congenital α-2-plasmin inhibitor deficiency: orthopedic surgery with protection by tranexamic acid. Haemostasis 1991;21:321-327.
19. [19] Laurell C-B. Quantitative estimation of proteins by electrophoresis in agarose get containing antibodies. Anal Biochem 1966;15:45-52.
20. [20] Yoshioka A, Kamitsuji H, Takase T, Iida S, Tsukada S, Mikami S, Fukui H. Congenital deficiency of α2-plasmin inhibitor in three sisters. Haemostasis 1982;11:176-184.
21. [21] Self J, Matthews C. Inherited fibrinolytic hyperactivity. Arch Intern Med 1968;122:357-358.
22. 2-plasmin inhibitor deficiency (Miyasato disease). Lancet 1979;11:1334-1336.
23. [23] Aoki N, Saito H, Kamiya T, Koie K, Sakata Y, Kobakura M. Congenital deficiency of α2-plasmin inhibitor associated with severe hemorrhagic tendency. J Clin Invest 1979;63:877-884.
24. [24] Aoki N. Hemostasis associated with abnormalities of fibrinolysis. Blood Rev 1989;3:11-17.